ReviewBMC microbiology2024
Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy.
Review in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical Characteristics and Antimicrobial Resistance Profiles of Pediatric Enterococcal Infections: A Comparison BetweenPathogens (Basel, Switzerland) · 2026Article
- Review
- Molecular mechanisms of virulence in Enterococcus faecium: integrating Esp, Acm, regulatory RNA networks in multidrug resistant nosocomial infections.Archives of microbiology · 2026Review
- First comprehensive molecular and phenotypic insights into multidrug resistance and virulence in poultry-associated Enterococcus spp. in Algeria.Molecular biology reports · 2026Article
- Methicillin-ResistantMicroorganisms · 2026Review
- Evaluation of the antibacterial activity of Akkermansia muciniphila extract against Enterococcus faecium isolates.Molecular biology reports · 2026Article
- Clinical and Genomic Characterization of Recalcitrant Enterococcal Bacteremia: A Multicenter Prospective Cohort Study (VENOUS).The Journal of infectious diseases · 2025Article
- Hidden diversity inMicrobiology spectrum · 2025Article
- Genomic Epidemiology of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- Deciphering vancomycin resistance inFrontiers in microbiology · 2025Article
- Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.Journal of agricultural and food chemistry · 2024Review
- Vancomycin-Resistant Enterococci: Current Understandings of Resistance in Relation to Transmission and Preventive Strategies.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Vancomycin-resistant enterococci (VRE) are major opportunistic pathogens and the causative agents of serious diseases, such as urinary tract infections and endocarditis. VRE strains mainly include species of Enterococcus faecium and E. faecalis which can colonise the gastrointestinal tract (GIT) of patients and, following growth and persistence in the gut, can transfer to blood resulting in systemic dissemination in the body. Advancements in genomics have revealed that hospital-associated VRE strains are characterised by increased numbers of mobile genetic elements, higher numbers of antibiotic resistance genes and often lack active CRISPR-Cas systems. Additionally, comparative genomics have increased our understanding of dissemination routes among patients and healthcare workers. Since the efficiency of currently available antibiotics is rapidly declining, new measures to control infection and dissemination of these persistent pathogens are urgently needed. These approaches include combinatory administration of antibiotics, strengthening colonisation resistance of the gut microbiota to reduce VRE proliferation through commensals or probiotic bacteria, or switching to non-antibiotic bacterial killers, such as bacteriophages or bacteriocins. In this review, we discuss the current knowledge of the genomics of VRE isolates and state-of-the-art therapeutic advances against VRE infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.